{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:51:57Z","timestamp":1781585517114,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403838"],"award-info":[{"award-number":["82403838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073404"],"award-info":[{"award-number":["82073404"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is the most aggressive primary malignant brain tumor, and while chimeric antigen receptor-T (CAR-T) cell therapy has shown promise, its efficacy remains limited by antigen heterogeneity and immune escape. Here, we investigated the expression of B7 homolog 3 (B7-H3), epidermal growth factor receptor (EGFR), and interleukin-13 receptor alpha 2 (IL-13RA2) in GBM tissues and cell lines. Although all three antigens were highly expressed, sustained exposure to B7-H3 CAR-T cells led to significant B7-H3 downregulation but concurrent EGFR upregulation, revealing a potential immune escape mechanism. To address this heterogeneity, we engineered T cells to express an anti-B7-H3 CAR and secrete an EGFR-targeting bispecific T-cell engager (EGFR-BsTe). These B7-H3-CAR-T-EGFR-BsTe cells exerted dual functionality: direct B7-H3-dependent cytotoxicity and recruitment of unmodified T cells via secreted EGFR-BsTe to eliminate EGFR-expressing tumor cells. Notably, EGFR-BsTe secretion promoted CAR-T cell proliferation and effector differentiation. In orthotopic GBM xenograft models, including mixed tumors with heterogeneous antigen expression, B7-H3-CAR-T-EGFR-BsTe cells demonstrated superior antitumor activity and prolonged survival compared to conventional B7-H3 CAR-T cells. Quantitative analysis revealed that EGFR-BsTe secretion abrogated EGFR upregulation and enhanced B7-H3 downregulation in a target-dependent manner; however, efficacy was diminished when the CAR-Target (B7-H3) was absent on a substantial fraction of tumor cells. Our findings suggest that arming B7-H3 CAR-T cells with EGFR-targeting bispecific engagers represents a promising strategy to overcome antigen heterogeneity and improve therapeutic outcomes for GBM patients.<\/jats:p>","DOI":"10.1186\/s43556-026-00492-7","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:57:35Z","timestamp":1781582255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression"],"prefix":"10.1186","volume":"7","author":[{"given":"Zongliang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-5443","authenticated-orcid":false,"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"492_CR1","doi-asserted-by":"publisher","first-page":"218185","DOI":"10.1016\/j.canlet.2025.218185","volume":"640","author":"T Jiang","year":"2026","unstructured":"Jiang T, Nam DH, Ram Z, Poo WS, Wang J, Boldbaatar D, et al. Updated clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2026;640:218185. https:\/\/doi.org\/10.1016\/j.canlet.2025.218185.","journal-title":"Cancer Lett"},{"key":"492_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41467-025-66747-z","volume":"17","author":"MA Vaz-Salgado","year":"2025","unstructured":"Vaz-Salgado MA, Del Barco S, Sepulveda JM, Alonso M, Pineda E, Balana C, et al. Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib\/II GEINO 1602 trial. Nat Commun. 2025;17:86. https:\/\/doi.org\/10.1038\/s41467-025-66747-z.","journal-title":"Nat Commun"},{"key":"492_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(25)02435-3","volume":"407","author":"ML Palomba","year":"2026","unstructured":"Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, et al. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026;407:963\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(25)02435-3.","journal-title":"Lancet"},{"key":"492_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","volume":"10","author":"AD Posey Jr.","year":"2024","unstructured":"Posey AD Jr., Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends Cancer. 2024;10:687\u201395. https:\/\/doi.org\/10.1016\/j.trecan.2024.05.007.","journal-title":"Trends Cancer"},{"key":"492_CR5","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","volume":"33","author":"MM Meehl","year":"2025","unstructured":"Meehl MM, Immadisetty K, Trivedi VD, Glowacki P, Prinzing B, Anido AA, et al. Computational structural optimization enhances IL13R\u03b12 \u2013 B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape. Mol Ther. 2025;33:4968\u201387. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.044.","journal-title":"Mol Ther"},{"key":"492_CR6","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/neuonc\/noaf064","volume":"27","author":"J Gust","year":"2025","unstructured":"Gust J, Cole BL, Ronsley R, Wilson AL, Seidel K, Wendler J, et al. Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: results of the completed BrainChild02 phase 1 clinical trial. Neuro Oncol. 2025;27:2170\u201381. https:\/\/doi.org\/10.1093\/neuonc\/noaf064.","journal-title":"Neuro Oncol"},{"key":"492_CR7","doi-asserted-by":"publisher","first-page":"e2400753","DOI":"10.1200\/PO-24-00753","volume":"9","author":"WK Gerber","year":"2025","unstructured":"Gerber WK, Xie Y, Patel SA. Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors. JCO Precis Oncol. 2025;9:e2400753. https:\/\/doi.org\/10.1200\/PO-24-00753.","journal-title":"JCO Precis Oncol"},{"key":"492_CR8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30:2537\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.011.","journal-title":"Mol Ther"},{"key":"492_CR9","doi-asserted-by":"publisher","first-page":"e202501772","DOI":"10.1002\/advs.202501772","volume":"12","author":"GD Zhu","year":"2025","unstructured":"Zhu GD, Sun ZZ, Liu YC, Liu J, Guo LP, Pei GJ, et al. Rational design and organoid-based evaluation of a cocktail CAR-\u03b3\u03b4 T cell therapy for heterogeneous glioblastoma. Adv Sci. 2025;12:e202501772. https:\/\/doi.org\/10.1002\/advs.202501772.","journal-title":"Adv Sci"},{"key":"492_CR10","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/neuonc\/noac204","volume":"24","author":"B Lin","year":"2022","unstructured":"Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, et al. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2022;24:2035\u201362. https:\/\/doi.org\/10.1093\/neuonc\/noac204.","journal-title":"Neuro Oncol"},{"key":"492_CR11","doi-asserted-by":"publisher","first-page":"113346","DOI":"10.1016\/j.isci.2025.113346","volume":"28","author":"J Qiu","year":"2025","unstructured":"Qiu J, Zhu F, Quan R, Ye H, Su W, Wang R, et al. Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma. iScience. 2025;28:113346. https:\/\/doi.org\/10.1016\/j.isci.2025.113346.","journal-title":"iScience"},{"key":"492_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer. 2024;5:517\u201331. https:\/\/doi.org\/10.1038\/s43018-023-00709-6.","journal-title":"Nat Cancer"},{"key":"492_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"492_CR14","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Wang RX, Liang TYZ, Ren H, Park C, Tai CH, et al. Camel nanobody-based B7\u2013H3 CAR-T cells show high efficacy against large solid tumours. Nat Commun. 2023;14:5920. https:\/\/doi.org\/10.1038\/s41467-023-41631-w.","journal-title":"Nat Commun"},{"key":"492_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","volume":"46","author":"DT Corrigan","year":"2025","unstructured":"Corrigan DT, Tanwar A, Du M, Martin AM, Zang X. The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics. Trends Pharmacol Sci. 2025;46:975\u201388. https:\/\/doi.org\/10.1016\/j.tips.2025.08.008.","journal-title":"Trends Pharmacol Sci"},{"key":"492_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","volume":"6","author":"X Tang","year":"2021","unstructured":"Tang X, Wang Y, Huang J, Zhang Z, Liu F, Xu J, et al. Administration of B7\u2013H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma. Signal Transduct Target Ther. 2021;6:125. https:\/\/doi.org\/10.1038\/s41392-021-00505-7.","journal-title":"Signal Transduct Target Ther"},{"key":"492_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 2023;13:114\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0750.","journal-title":"Cancer Discov"},{"key":"492_CR18","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1200\/JCO.2024.42.16_suppl.2062","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Feng R, Chi XH, Xian N, Chen XZ, Huang N, et al. Safety and efficacy of B7\u2013H3 targeting CAR-T cell therapy for patients with recurrent GBM. J Clin Oncol. 2024;42:2062. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2062.","journal-title":"J Clin Oncol"},{"key":"492_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/08830185.2022.2102619","volume":"41","author":"G Li","year":"2022","unstructured":"Li G, Wang H, Wu H, Chen J. B7\u2013H3-targeted CAR-T cell therapy for solid tumors. Int Rev Immunol. 2022;41:625\u201337. https:\/\/doi.org\/10.1080\/08830185.2022.2102619.","journal-title":"Int Rev Immunol"},{"key":"492_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, et al. Locoregionally administered B7\u2013H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med. 2020;26:712\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0821-8.","journal-title":"Nat Med"},{"key":"492_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omto.2022.08.008","volume":"26","author":"K Birley","year":"2022","unstructured":"Birley K, Leboreiro-Babe C, Rota EM, Buschhaus M, Gavriil A, Vitali A, et al. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers. Mol Ther Oncolytics. 2022;26:429\u201343. https:\/\/doi.org\/10.1016\/j.omto.2022.08.008.","journal-title":"Mol Ther Oncolytics"},{"key":"492_CR22","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25:2560\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432.","journal-title":"Clin Cancer Res"},{"key":"492_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35:221-37.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.002.","journal-title":"Cancer Cell"},{"key":"492_CR24","doi-asserted-by":"publisher","unstructured":"Tang X, Liu F, Liu Z, Cao Y, Zhang Z, Wang Y, et al. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma. Clin Transl Immunology. 2020;9:e1137https:\/\/doi.org\/10.1002\/cti2.1137","DOI":"10.1002\/cti2.1137"},{"key":"492_CR25","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30:1320\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","journal-title":"Nat Med"},{"key":"492_CR26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390:1290\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2314390.","journal-title":"N Engl J Med"},{"key":"492_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-med-042921-024719","volume":"74","author":"F Furqan","year":"2023","unstructured":"Furqan F, Shah NN. Multispecific CAR T cells deprive lymphomas of escape via antigen loss. Annu Rev Med. 2023;74:279\u201391. https:\/\/doi.org\/10.1146\/annurev-med-042921-024719.","journal-title":"Annu Rev Med"},{"key":"492_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24:126. https:\/\/doi.org\/10.1186\/s12943-025-02334-6.","journal-title":"Mol Cancer"},{"key":"492_CR29","doi-asserted-by":"publisher","first-page":"e009604","DOI":"10.1136\/jitc-2024-009604","volume":"12","author":"DH Park","year":"2024","unstructured":"Park DH, Bhojnagarwala PS, Liaw K, Bordoloi D, Tursi NJ, Zhao S, et al. Novel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells. J Immunother Cancer. 2024;12:e009604. https:\/\/doi.org\/10.1136\/jitc-2024-009604.","journal-title":"J Immunother Cancer"},{"key":"492_CR30","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","volume":"31","author":"SJ Bagley","year":"2025","unstructured":"Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, et al. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med. 2025;31:2778\u201387. https:\/\/doi.org\/10.1038\/s41591-025-03745-0.","journal-title":"Nat Med"},{"key":"492_CR31","doi-asserted-by":"publisher","unstructured":"Guan J, Zhang X, Wu W, Cao L, Liao Z, Zhu T, et al. Abstract LB055: IBI3001: A potentially first-in-class site-specifically conjugated B7-H3\/EGFR bispecific ADC for multiple solid tumors. Cancer Research. 2024;84:LB055. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-LB055","DOI":"10.1158\/1538-7445.AM2024-LB055"},{"key":"492_CR32","doi-asserted-by":"publisher","first-page":"102991","DOI":"10.1016\/j.ctrv.2025.102991","volume":"139","author":"ZM Zair","year":"2025","unstructured":"Zair ZM, Butterworth G, Shalaby M, Ostarijas E, Thisthlethwaite F. T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis. Cancer Treat Rev. 2025;139:102991. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102991.","journal-title":"Cancer Treat Rev"},{"key":"492_CR33","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.3390\/ijms26125838","volume":"26","author":"KS Shan","year":"2025","unstructured":"Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, Dalal M, Ferraro P, et al. Bispecific antibodies in solid tumors: advances and challenges. Int J Mol Sci. 2025;26:5838. https:\/\/doi.org\/10.3390\/ijms26125838.","journal-title":"Int J Mol Sci"},{"key":"492_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"key":"492_CR35","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/2159-8290.CD-23-1226","volume":"13","author":"JM Donaldson","year":"2023","unstructured":"Donaldson JM, Seddiq M, Fusco MJ, Singla S, Pamuk GE, Lee-Alonso RJ, et al. Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer Discov. 2023;13:2515\u201324. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1226.","journal-title":"Cancer Discov"},{"key":"492_CR36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.tips.2023.09.009","volume":"44","author":"T Qi","year":"2023","unstructured":"Qi T, Liao X, Cao Y. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends Pharmacol Sci. 2023;44:880\u201390. https:\/\/doi.org\/10.1016\/j.tips.2023.09.009.","journal-title":"Trends Pharmacol Sci"},{"key":"492_CR37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21:1354\u201375. https:\/\/doi.org\/10.1038\/s41423-024-01226-x.","journal-title":"Cell Mol Immunol"},{"key":"492_CR38","doi-asserted-by":"publisher","first-page":"217928","DOI":"10.1016\/j.canlet.2025.217928","volume":"631","author":"Z Li","year":"2025","unstructured":"Li Z, Yang F, Lu S, Wu X, Li S, Wang M. Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation. Cancer Lett. 2025;631:217928. https:\/\/doi.org\/10.1016\/j.canlet.2025.217928.","journal-title":"Cancer Lett"},{"key":"492_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.11.010","author":"M Logun","year":"2025","unstructured":"Logun M, Wang X, Sun YS, Bagley SJ, Li NN, Desai A, et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell. 2025. https:\/\/doi.org\/10.1016\/j.stem.2024.11.010.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"492_CR40","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1002\/mco2.437","volume":"2023","author":"H Xu","year":"2020","unstructured":"Xu H, Jia Z, Liu F, Li J, Huang Y, Jiang Y, et al. Biomarkers and experimental models for cancer immunology investigation. MedComm. 2020;2023(4):e437. https:\/\/doi.org\/10.1002\/mco2.437.","journal-title":"MedComm"},{"key":"492_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","volume":"4","author":"F Cattaruzza","year":"2023","unstructured":"Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, et al. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nat Cancer. 2023;4:485\u2013501. https:\/\/doi.org\/10.1038\/s43018-023-00536-9.","journal-title":"Nat Cancer"},{"key":"492_CR42","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1158\/0008-5472.Can-21-2483","volume":"82","author":"LM Boustany","year":"2022","unstructured":"Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, et al. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. Can Res. 2022;82:4288\u201398. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-2483.","journal-title":"Can Res"},{"key":"492_CR43","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.3390\/ijms25137131","volume":"25","author":"S Tardito","year":"2024","unstructured":"Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A. Epidermal growth factor receptor targeting in colorectal carcinoma: antibodies and patient-derived organoids as a smart model to study therapy resistance. Int J Mol Sci. 2024;25:7131. https:\/\/doi.org\/10.3390\/ijms25137131.","journal-title":"Int J Mol Sci"},{"key":"492_CR44","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1016\/j.ymthe.2025.09.026","volume":"33","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Li Z, Shen X, Halladay T, Tse C, et al. Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety. Mol Ther. 2025;33:6041\u201362. https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.026.","journal-title":"Mol Ther"},{"key":"492_CR45","doi-asserted-by":"publisher","unstructured":"Giglio RM, Hou N, Wyatt A, Hong J, Shi L, Vaikunthan M, et al. A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase. bioRxiv. 2025; https:\/\/doi.org\/10.1101\/2024.04.08.587960","DOI":"10.1101\/2024.04.08.587960"},{"key":"492_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-023-03875-4","volume":"21","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang G, Zhong K, Chen Y, Yang N, Lu Q, et al. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy. J Transl Med. 2023;21:23. https:\/\/doi.org\/10.1186\/s12967-023-03875-4.","journal-title":"J Transl Med"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00492-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:57:38Z","timestamp":1781582258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00492-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00492-7","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient samples were obtained under approved by the Ethics Committee of the Mianyang Central Hospital, and the study was conducted in accordance with the donors provided informed consent (ethical approval document: s20240328-02). Animal experiments were conducted using protocols approved by the Institutional Animal Care and Use Committee of Sichuan University (ethical approval document: 20230426002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients provided written informed consent prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}